

Resource Summary Report

Generated by ASWG on Aug 11, 2026

Stat5 (pY694)

RRID:AB_11154412

Type: Antibody

Proper Citation

BD Biosciences Cat# 562076, RRID:AB_11154412

Antibody Information

URL: http://antibodyregistry.org/AB_11154412

Proper Citation: BD Biosciences Cat# 562076, RRID:AB_11154412

Target Antigen: Stat5 (pY694)

Host Organism: mouse

Clonality: monoclonal

Comments: Intracellular staining (flow Cytotoxicityometry)

Antibody Name: Stat5 (pY694)

Description: This monoclonal targets Stat5 (pY694)

Target Organism: human

Antibody ID: AB_11154412

Vendor: BD Biosciences

Catalog Number: 562076

Record Creation Time: 20250819T232526+0000

Record Last Update: 20250820T051742+0000

Ratings and Alerts

No rating or validation information has been found for Stat5 (pY694).

No alerts have been found for Stat5 (pY694).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Jin Z, et al. (2026) Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. British journal of pharmacology, 183(11), 3074.

Wang L, et al. (2025) CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell reports. Medicine, 6(1), 101889.

Silver AB, et al. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell reports. Medicine, 4(11), 101289.

Fang Z, et al. (2023) Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nature communications, 14(1), 7725.

Kan WL, et al. (2023) Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. Cancer discovery, 13(8), 1922.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell reports, 41(3), 111478.

Wagner JA, et al. (2020) Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell reports, 31(9), 107720.

Berrien-Elliott MM, et al. (2019) MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 51(3), 479.